文献速递白血病

衔接蛋白介导的FLT3信号重塑激活p38 MAPK维持急性髓系白血病对吉瑞替尼耐药

Adaptor-mediated rewiring of FLT3 signaling engages p38 MAPK to sustain gilteritinib resistance in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2026-07-29

该研究在吉瑞替尼耐药AML细胞中进行全激酶组CRISPR-Cas9筛选,发现MAPK14(p38α)而非ERK1/2是耐药状态下的关键依赖。耐药细胞通过p46-SHC1衔接蛋白重塑FLT3信号,维持MKK3/6-p38模块及MYC表达,支持细胞在持续药物暴露下存活;抑制p38可增强吉瑞替尼敏感性并协同抑制白血病生长。

要点

  • 吉瑞替尼耐药AML细胞依赖p38α而非ERK1/2信号存活。
  • p46-SHC1介导的FLT3-MKK3/6-p38信号模块在FLT3抑制下仍持续激活。
  • 抑制p38可恢复吉瑞替尼敏感性并协同抑制白血病生长。

核心结论

  • FLT3抑制剂耐药AML存在非经典MAPK信号状态,p38α是耐药状态下的关键依赖。
  • 靶向p38等应激适应通路可能提高FLT3靶向治疗的持久性。

研究设计与样本

  • 在吉瑞替尼耐药AML细胞中进行无偏倚全激酶组CRISPR-Cas9筛选。
  • 结合遗传损伤和药理学抑制验证p38在耐药中的作用。

主要发现

  • 筛选鉴定出MAPK14(编码p38α)而非MAPK3/MAPK1(编码ERK1/2)为耐药相关的情境依赖性依赖。
  • 耐药细胞中p46-SHC1支持FLT3相关的MKK3/6-p38信号模块,维持MYC表达等下游程序。
  • 遗传或药理学抑制p38增强吉瑞替尼敏感性并协同抑制白血病生长。

临床怎么用

  • 对FLT3突变AML患者,吉瑞替尼耐药后可考虑检测p38通路激活状态。
  • p38抑制联合FLT3抑制剂可能作为克服耐药的策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistance to FLT3 inhibitors remains a major limitation in the treatment of FLT3-mutated acute myeloid leukemia (AML). Canonically, ERK is considered the predominant MAPK effector downstream of FLT3 signaling. However, pharmacologic inhibition of MEK/ERK provides limited clinical benefit once resistance develops, suggesting that alternative signaling dependencies may emerge under therapeutic pressure. Using an unbiased kinome-wide CRISPR-Cas9 screen in gilteritinib-resistant AML cells, we identified MAPK14 (encoding p38α), rather than MAPK3/MAPK1 (encoding ERK1/2), as a prominent context-dependent dependency associated with the resistant state. Genetic impairment or pharmacologic inhibition of p38 enhanced gilteritinib sensitivity and synergized with FLT3 inhibition to suppress leukemic growth. Mechanistically, resistant cells exhibited adaptor-mediated rewiring of FLT3 signaling, in which p46-SHC1 supported an FLT3-associated MKK3/6-p38 signaling module despite FLT3 inhibition, thereby sustaining downstream programs including MYC expression. Consistent with its role as a stress-responsive kinase, p38 supports leukemic cell survival under prolonged drug exposure. Together, these findings define a non-canonical MAPK signaling state associated with FLT3 inhibitor resistance, provide a mechanistic explanation for the limited efficacy of MEK/ERK-directed therapies in the resistant setting, and offer a rationale for combination strategies targeting stress-adaptive pathways to improve the durability of FLT3-directed therapy in AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Shen L, Fan J, Wang N, et al. Adaptor-mediated rewiring of FLT3 signaling engages p38 MAPK to sustain gilteritinib resistance in acute myeloid leukemia. Leukemia. 2026. PMID: 42527666. doi:10.1038/s41375-026-03079-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。